|
Ziliak, Dana; O'Donnell, Peter H; Im, Hae Kyung et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157:265-72
|
|
Horton, Terzah M; Jenkins, Gaye; Pati, Debananda et al. (2009) Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8:2232-42
|
|
Horton, Terzah M; Thompson, Patrick A; Berg, Stacey L et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol 25:4922-8
|
|
Ryan, Christopher W; Dolan, M Eileen; Brockstein, Bruce B et al. (2006) A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 58:634-9
|
|
Winquist, Eric; Vokes, Everett; Moore, Malcolm J et al. (2005) A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol 23:150-4
|
|
Mauer, A M; Kraut, E H; Krauss, S A et al. (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16:1320-5
|
|
Desai, Apurva A; Kindler, Hedy L; Taber, David et al. (2005) Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol 56:421-6
|
|
Kindler, Hedy L; Tothy, Peter K; Wolff, Robert et al. (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23:489-93
|
|
Winegarden, J D; Mauer, A M; Otterson, G A et al. (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15:915-20
|
|
Kindler, Hedy L; Avadhani, Anjali; Wade-Oliver, Kurombi et al. (2004) 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs 22:323-7
|
Showing the most recent 10 out of 25 publications
